EUVIMEDEUVIMED entdecken
Crossref

Discovery and Optimization of Isoform Selective ULK1 Degraders to Enhance Antitumor Activity in KRAS-Mutant Cancer

Sean Chin Chan iD, Simon Bayle, Micheal Lamptey, Ansar Lee-Sam iD, Luxin Sun iD, Dylan Grassie iD, Ramu Kakumanu, Samer Sansil, Ernst Schönbrunn iD, Derek R Duckett, Andrii Monastyrskyi iD

Journal of Medicinal Chemistry · 22.10.2026 · 69 (20) · 23744-23769

DOI: 10.1021/acs.jmedchem.6c01340 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 07.10.2026. Verfasst von Sean Chin Chan und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Drug Discovery, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida33612, United States. Hauptthemen laut MEDLINE: Autophagy-Related Protein-1 Homolog, Antineoplastic Agents, Proto-Oncogene Proteins p21(ras), Intracellular Signaling Peptides and Proteins. Die Arbeit nennt 41 Literaturangaben. Gefördert von: ORIP NIH HHS, NCI NIH HHS, Office of Research Infrastructure Programs.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Selective targeting of ULK1 represents a promising approach to overcome autophagy-mediated resistance in KRAS-driven cancers. However, achieving selectivity over the closely related ULK2 isoform with ATP-competitive inhibitors remains challenging due to the high sequence homology within their kinase domains. Here, we describe the design, synthesis, and structure−degradation relationship studies of two cereblon-recruiting ULK1 degraders, MR-9034 and MR-9036. Structure-guided optimization led to the discovery of MR-9036 as a potent and selective ULK1 PROTAC that degrades ULK1 without affecting ULK2 or IMiD neo-substrates. Cellular and biophysical studies confirm ternary complex formation and proteasome-dependent degradation. Compared with the clinical ULK1/2 inhibitor DCC-3116, MR-9036 produces sustained autophagy suppression following compound washout. In KRASG12C-mutant NSCLC models, ULK1 degradation enhances the antiproliferative activity of sotorasib. Pharmacokinetic/pharmacodynamic (PK/PD) studies in mice support in vivo feasibility. These findings establish selective ULK1 degradation as a chemical strategy to interrogate ULK1 biology and enhance therapeutic response in KRAS-driven cancers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Autophagy-Related Protein-1 HomologAntineoplastic AgentsProto-Oncogene Proteins p21(ras)Intracellular Signaling Peptides and ProteinsProtein Kinase InhibitorsHumansAnimalsStructure-Activity RelationshipMiceMutationCell Line, TumorProteolysisDrug DiscoveryProtein IsoformsCell ProliferationProteolysis Targeting Chimera

Stichwörter der Autor:innen

7-azaindolePROTACsULK1autophagydegraderkinase

Substanzen

Autophagy-Related Protein-1 HomologAntineoplastic AgentsProto-Oncogene Proteins p21(ras)Intracellular Signaling Peptides and ProteinsULK1 protein, humanKRAS protein, humanProtein Kinase InhibitorsProtein IsoformsProteolysis Targeting Chimera

Autor:innen und Institutionen

  • Department of Drug Discovery, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida33612, United States.
  • Cancer Chemical Biology Ph.D. Program, University of South Florida/H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida33620, United States.
  • Cancer Biology Ph.D. Program, University of South Florida/H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida33620, United States.
  • Cancer PK/PD Core, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida33612, United States.

ORCID-Profile: Sean Chin Chan, Ansar Lee-Sam, Luxin Sun, Dylan Grassie, Ernst Schönbrunn, Andrii Monastyrskyi

Förderung

  • ORIP NIH HHS
  • NCI NIH HHS
  • Office of Research Infrastructure Programs
  • National Cancer Institute

Zitieren

APA

Chin Chan, S., Bayle, S., Lamptey, M., Lee-Sam, A., Sun, L., Grassie, D., Kakumanu, R., Sansil, S., Schönbrunn, E., Duckett, D. R., & Monastyrskyi, A. (2026). Discovery and Optimization of Isoform Selective ULK1 Degraders to Enhance Antitumor Activity in KRAS-Mutant Cancer. Journal of Medicinal Chemistry, 69(20), 23744-23769. https://doi.org/10.1021/acs.jmedchem.6c01340

Vancouver

Chin Chan S, Bayle S, Lamptey M, Lee-Sam A, Sun L, Grassie D, et al. Discovery and Optimization of Isoform Selective ULK1 Degraders to Enhance Antitumor Activity in KRAS-Mutant Cancer. Journal of Medicinal Chemistry. 2026;69(20):23744-23769. doi:10.1021/acs.jmedchem.6c01340

BibTeX
@article{ChinChan2026,
  author = {Chin Chan, Sean and Bayle, Simon and Lamptey, Micheal and Lee-Sam, Ansar and Sun, Luxin and Grassie, Dylan and Kakumanu, Ramu and Sansil, Samer and Schönbrunn, Ernst and Duckett, Derek R and Monastyrskyi, Andrii},
  title = {Discovery and Optimization of Isoform Selective ULK1 Degraders to Enhance Antitumor Activity in KRAS-Mutant Cancer},
  journal = {Journal of Medicinal Chemistry},
  year = {2026},
  volume = {69},
  number = {20},
  pages = {23744--23769},
  doi = {10.1021/acs.jmedchem.6c01340}
}
Kostenlos starten →